MDWD vs. NUVB, CRON, PHVS, EOLS, XERS, LENZ, IMNM, RCKT, XNCR, and ABUS
Should you be buying MediWound stock or one of its competitors? The main competitors of MediWound include Nuvation Bio (NUVB), Cronos Group (CRON), Pharvaris (PHVS), Evolus (EOLS), Xeris Biopharma (XERS), LENZ Therapeutics (LENZ), Immunome (IMNM), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.
MediWound vs.
Nuvation Bio (NYSE:NUVB) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
Nuvation Bio has a net margin of 0.00% compared to MediWound's net margin of -142.29%. Nuvation Bio's return on equity of -21.89% beat MediWound's return on equity.
Nuvation Bio presently has a consensus price target of $8.75, suggesting a potential upside of 323.73%. MediWound has a consensus price target of $31.33, suggesting a potential upside of 74.56%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nuvation Bio is more favorable than MediWound.
MediWound has higher revenue and earnings than Nuvation Bio. MediWound is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.
MediWound received 343 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 81.82% of users gave Nuvation Bio an outperform vote while only 62.23% of users gave MediWound an outperform vote.
61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 5.1% of Nuvation Bio shares are owned by insiders. Comparatively, 9.2% of MediWound shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Nuvation Bio has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.
In the previous week, Nuvation Bio had 3 more articles in the media than MediWound. MarketBeat recorded 5 mentions for Nuvation Bio and 2 mentions for MediWound. Nuvation Bio's average media sentiment score of 1.42 beat MediWound's score of 0.34 indicating that Nuvation Bio is being referred to more favorably in the media.
Summary
Nuvation Bio beats MediWound on 14 of the 18 factors compared between the two stocks.
Get MediWound News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediWound Competitors List
Related Companies and Tools
This page (NASDAQ:MDWD) was last updated on 4/22/2025 by MarketBeat.com Staff
